Imlunestrant

Chemical formula: C₂₉H₂₄F₄N₂O₃  Molecular mass: 524.172 g/mol  PubChem compound: 146603228

Therapeutic indications

Imlunestrant is indicated for:

ER-positive, HER2-negative breast cancer with an activating ESR1-mutation

Population group: only adults (18 years old or older)

Imlunestrant is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen.

In pre- or perimenopausal women, or men, imlunestrant should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈